Skip to main content
Journal cover image

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Publication ,  Journal Article
Reardon, DA; Norden, AD; Desjardins, A; Vredenburgh, JJ; Herndon, JE; Coan, A; Sampson, JH; Gururangan, S; Peters, KB; McLendon, RE; Lipp, ES ...
Published in: J Neurooncol
January 2012

We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg/day for patients not on CYP3A enzyme inducing anti-epileptic drugs (EIAEDs) and at 500 mg twice a day for patients on EIAEDs. The primary endpoint was progression-free survival at 6 months (PFS-6) and secondary endpoints were safety, radiographic response rate, and overall survival (OS). Best radiographic response was stable disease and was observed in 14 patients (67%). PFS-6 for all patients, those with grade I tumors (n = 8) and those with grade II or III tumors (n = 13) was 61.9, 87.5 and 46.2%, respectively. Patients with grade II or III tumors had poorer PFS and OS than those with grade I tumors, (P = 0.025 and P = 0.018) respectively. The only grade 3 or greater adverse event occurring in ≥ 10% of patients was anemia (10%). Imatinib plus hydroxyurea is well tolerated among patients with meningioma but has modest anti-tumor activity for this indication.

Duke Scholars

Published In

J Neurooncol

DOI

EISSN

1573-7373

Publication Date

January 2012

Volume

106

Issue

2

Start / End Page

409 / 415

Location

United States

Related Subject Headings

  • Pyrimidines
  • Piperazines
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Neoplasm Grading
  • Middle Aged
  • Meningioma
  • Meningeal Neoplasms
  • Male
  • Kaplan-Meier Estimate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Norden, A. D., Desjardins, A., Vredenburgh, J. J., Herndon, J. E., Coan, A., … Friedman, H. S. (2012). Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol, 106(2), 409–415. https://doi.org/10.1007/s11060-011-0687-1
Reardon, David A., Andrew D. Norden, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, John H. Sampson, et al. “Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.J Neurooncol 106, no. 2 (January 2012): 409–15. https://doi.org/10.1007/s11060-011-0687-1.
Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, et al. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan;106(2):409–15.
Reardon, David A., et al. “Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.J Neurooncol, vol. 106, no. 2, Jan. 2012, pp. 409–15. Pubmed, doi:10.1007/s11060-011-0687-1.
Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan;106(2):409–415.
Journal cover image

Published In

J Neurooncol

DOI

EISSN

1573-7373

Publication Date

January 2012

Volume

106

Issue

2

Start / End Page

409 / 415

Location

United States

Related Subject Headings

  • Pyrimidines
  • Piperazines
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Neoplasm Grading
  • Middle Aged
  • Meningioma
  • Meningeal Neoplasms
  • Male
  • Kaplan-Meier Estimate